Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Sex Transm Dis. 2011 Nov;38(11):1074–1081. doi: 10.1097/OLQ.0b013e31822e60cb

Table 3.

Hazard ratios for risk of type-specifica HPV acquisition at any genital site by circumcision status.

Clinically-relevant
HPVb 		High-risk HPVc HPV 16 Alpha 9d Alpha 7e
Hazard
Ratio
(95% CI)		 No.
Infections/
No.
Person-
years at
Risk		 Hazard
Ratio
(95% CI)		 No.
Infections/
No.
Person-
years at
Risk		 Hazard
Ratio
(95% CI)		 No.
Infections/
No.
Person-
years at
Risk		 Hazard
Ratio
(95% CI)		 No.
Infections/
No.
Person-
years at
Risk		 Hazard
Ratio
(95% CI)		 No.
Infections/
No.
Person-
years at
Risk
Circumcisedf 1.0 500/14777 1.0 458/13364 1.0 75/610 1.0 143/4203 1.0 118/3499
Uncircumcised 0.9 (0.7, 1.2) 165/5031 0.9 (0.7, 1.3) 153/4547 1.2 (0.8, 1.9) 31/ 200 1.3 (0.9, 1.9) 64/1413 0.7 (0.5, 1.04) 30/1208
a

Type-specific acquisition is defined as the first detection of an HPV type at any genital site.

b

Clinically-relevant types were defined as high or probable high-risk types plus HPV6 and HPV11.

c

High or probable high risk types were defined as HPV16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82, and IS39, as defined in the cervical cancer literature.

d

Alpha 9 group (HPV16, 31, 33, 35, 52, and 58; excluding low risk type HPV70).

e

Alpha 7 group (HPV18, 39, 45, 59, and 68; excluding low risk type HPV67).

f

The circumcised group was the referent group.